CAW
ENTA icon

Cornerstone Advisors (Washington)’s Enanta Pharmaceuticals ENTA Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-733
Closed -$22K – 875
2016
Q1 		$22K Hold
733
– – 0.02% 271
2015
Q4 		$24K Hold
733
– – 0.03% 285
2015
Q3 		$26K Buy
+733
New +$31.5K 0.02% 271

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Cornerstone Advisors (Washington)'s ENTA Position: Q2 2016 in Review

Cornerstone Advisors (Washington) sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 733 shares — an estimated $22K sold.

Cornerstone Advisors (Washington) first reported a position in ENTA in Q3 2015 and held it in 3 quarters. The position peaked at $26K in Q3 2015. 129 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • Cornerstone Advisors (Washington) reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 733 Enanta Pharmaceuticals shares in Q2 2016, an estimated $22K.
  • Cornerstone Advisors (Washington) first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Cornerstone Advisors (Washington)'s Enanta Pharmaceuticals position peaked at $26K in Q3 2015.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q2 2016, filed 25 Jul 2016.